ArticleNPJ precision oncology2026
Towards the tumor microenvironment scoring methods for immune checkpoint inhibitor response.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) have significantly changed cancer therapy, yet their response rates remain relatively low. Identifying methods for robust prediction is crucial. This study evaluates the efficacy of gene-based methods for deriving predictive tumor-microenvironment scores in cancer patients, focusing on their performances in predicting survival outcomes and response to ICI therapy across various cancer types. The TIP Hot method demonstrated robustness as a predictive method for ICI response, particularly in Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and Urothelial Cancer. However, no score is robustly applicable to all cancer types. Therefore, significant challenges remain due to the variability of tumor biology and host immune responses, and universally applicable method should be further explored. Future research should aim to refine these predictive scoring methods through larger and more diverse datasets, and integrate advanced computational techniques to enhance predictive accuracy and utility in personalized cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.